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Summary: A national audit of 781 early syphilis cases presenting during 2002-03 in UK 
genitourinary medicine clinics was conducted in late 2004, organised through the Regional 
Audit Groups. Data were aggregated by Region and NHS Trust, allowing practice to be 
compared between Regions, between Trusts within Regions, as well as to national averages 
and the UK National Guidelines. An enzyme immunoassay was used to diagnose 659 (89%) 
cases (regional range 18-100%). Use of a non-treponemal test was not recorded for 44 (6%) 
cases. Dark ground microscopy was used in the diagnosis of only 80 (29%) primary cases. 
Uptake of HIV testing was 77% (range 69-94%). Nationally, 527 (67%) treatments were 
parenteral, with almost equal use of benzathine penicillin G for 262 (50%, range 0–97%) cases 
and procaine penicillin G (PPG) for 260 cases (49%, range 3-100%). There were 14 (5%) 
treatments with less than the recommended 750mg dose of PPG. One hundred and five (40%) 
PPG treatments were with greater than 750mg and/or for longer than 10 days of which 76 
(72%) were for early latent syphilis and/or cases with HIV infection. One hundred and ninety two 
(86%, range 0-100%) of all oral treatments were with doxycycline. The recommended regimen 
of 100mg doxycycline twice daily for 14 days was used for 104 (53%) cases; the other 91 (47%) 
treatments were with a variety of regimens, mainly treatments with larger doses and/or longer 
treatment intervals and some combination treatments. Fourteen (2%) cases were not treated; 
treatment was not reported for 7 (0.9%) and not known for 10 (1.3%) cases who were treated at 
other centres.  
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Introduction 
In view of recent outbreaks of infectious syphilis in the UK,1 the National Audit Group (NAG) of 
the British Association for Sexual Health and HIV (BASHH) undertook an audit of early syphilis 
management in the UK in late 2004.  
 
Objectives & goal 
The objectives were to provide data to allow comparison of practice against national standards 
and guidelines, and against average UK performances, as well as to allow comparisons 
between Regions and between Trusts within Regions. The goal of the audit was to improve the 
management of early syphilis in the UK.  
 
Methods 
The Audit methodology and organisation was planned by the NAG, involving Chairs of all the 
Regional Audit Groups in the UK and an NHS Trust Clinical Audit expert. The standards and 
guidelines used were the UK National Guidelines on the Management of Early Syphilis 
produced by the Clinical Effectiveness Group (CEG) of BASHH.2 These provide a series of 
statements about practice against which performance can be compared, including diagnosis, 
treatment, follow-up, contact tracing and outcomes. Consensus was reached on a final version 
of audit questions and two questionnaires were produced, one for audit of case note data and 
the other for audit of individual clinic screening and management policies. These questionnaires 
are available on the BASHH website.3 The audit interval was for cases first attending between 1 
April 2002 and 31 March 2003. 
  
Case definition was a case of early syphilis diagnosed within the audit interval, and case finding 
was based on diagnostic codes A1, A2 or A3 of the statutory KC60 and ISD(D)5 returns.4 The 
number of cases suggested was: single doctor clinic - first 10 cases; 2 doctors - first 20 cases; 
larger centres - first 30 cases during the audit interval. The following process was used to 
collect data. The audit questionnaires were translated into an electronic form that was emailed 
to Regional Chairs in the form of a Microsoft Access database. The paper questionnaires were 
sent to clinics in Regions by the Regional Chairs; pseudonymised data were collected by clinics 
on the paper questionnaires and returned to Regional Chairs. The databases were populated by 
the offices of Regional Chairs from the completed paper questionnaires and returned by email 
to a central office. These data were returned during September to December 2004, and collated 
and aggregated by Region and by NHS Trusts/Clinics within Regions.   
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This paper reports on data obtained from the case notes part of the audit with regards to 
demographic features of the sample, as well as performance data in terms of national and 
regional averages, and regional ranges, relating to the use of diagnostic tests and treatments. 
Data aggregated by Regions is available on the BASHH website and allows comparisons to be 
made between Regions. Data aggregated by NHS Trusts within Regions has been provided to 
Chairs of Regional Audit Groups to allow service comparisons between Trusts.  
 
 
Results 
Sampling and demography 
 
Nationally, 16 of the 17 UK Regions participated, contributing a total of 781 cases made up of 
702, 49 and 30 cases from England, Scotland and Northern Ireland respectively. There were a 
total of 2694 diagnoses of early syphilis reported during the Audit interval (personal 
communications – see acknowledgements), comprising 1941 primary and secondary diagnoses 
and 671 early latent diagnoses in England, 37 primary and secondary cases and 16 early latent 
diagnoses in Scotland, and 25 primary and secondary diagnoses and 4 early latent diagnoses 
in Northern Ireland. Hence, 27%, 92% and 100% of early syphilis cases in England, Scotland 
and Northern Ireland, respectively, were sampled. Contribution of cases from the Regions 
ranged from 1-15%, and 255 (33%) cases were from within the 3 London Regions. The Region 
outside London with the greater number of cases was the North West with 103 (13%) cases. 
One hundred and forty four clinics took part in the Audit and 107 of these contributed cases.  
 
Nationally, there was even distribution of cases over the age range 26-40 years (419, 54%); 40 
(5%) cases were aged <20 years and 71 (9%) cases were aged > 50 years. There were 665 
(85%, range 67-100%) male cases and 116 (15%, range 0-33%) female cases, of whom 26 
(22%, range 0-100%) were pregnant. There was a preponderance of female cases in the South 
of England with 61 (52%) in South Thames and Anglia. Nationally 14 (54%) pregnant women 
were from non-White ethnic groups.  
 
The majority of cases were homosexual men, 465 (60%, range 33-93%), with heterosexual men 
164 (21%, range 0-56%), heterosexual women 110 (14%, range 0-33%), bisexual men 33 (4%, 
range, 0-12%); there were 3 homosexual women, and 1 bisexual woman, and sexual 
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preference was not known for 5 cases. The majority were of white ethnic groups, 597 (76%, 
range 56-100%), with 154 (20%, range 0-40%) from other ethnic groups, comprising: Black 99 
(13%, range 0-33%); Asian/Asian British 40 (5%, range 0-12%); Mixed 8 (1%, range 0-3%), and 
Chinese/Other 7 (1%, range 0-2%). The ethnic group was not recorded for 30 cases (4%, range 
0-21%). Of 56 Black Caribbean cases, 41 (73%) were in South London, and 23 (58%) of 40 
Black African cases were in South London and Anglia.  
 
The following stages of early syphilis were reported: primary 279 (36%, range 0-52%), 
secondary 250 (32%, range 11-71%), and early latent 247 (32%, range 4-67%). Stage was 
classified as “re-infection” for one case and not recorded for 4 cases. Nationally, 477 (61%, 
range 33-83%) cases were symptomatic, with 244 (87%, range 67-100%) primary cases, 198 
(79%, range 0-100%) secondary cases and 33 (13%, range 0-100%) early latent cases having 
symptoms.  
 
 
Use of diagnostic tests 
 
Table 1 shows the use of diagnostic tests. The audit question about use of tests to diagnose 
syphilis asked whether or not particular tests were done, and data were not collected about the 
temporal sequence of the use of these tests. In most cases (695, 89%, range 18-100%) an EIA 
was done, with 644 (82%, range 17-100%) having an EIA and either TPPA or TPHA tests. The 
following number of negative test results/total of positive, negative, equivocal and intermediate 
results were reported for each test in primary syphilis cases: EIA 7/249 (2.8%), TPPA 3/197 
(1.5%), TPHA 4/66 (6.0%), FTA abs 4/63 (6.3%), VDRL 40/190 (21.0%), RPR 21/98 (21.4%), 
DGM 47/80 (58.8%). In cases of secondary syphilis, there were no negative EIA or FTA abs 
results, but there was one negative TPPA test, one negative TPHA test, 9 negative VDRL tests 
and 5 negative RPR tests. One hundred and twelve FTA abs tests were done when both an EIA 
and either the TPPA or TPHA tests were positive, representing 62% of the total FTA abs tests 
done. In no case was an EIA and FTA abs done, when the response to testing with TPPA/TPHA 
was not done or not answered, suggesting that the FTA abs is (appropriately) not used as a 
confirmatory test instead of TPPA/TPHA tests. There were 38 (5%) cases where both TPPA 
and TPHA tests were done, although there is usually no advantage in doing both these tests.  
 
Final 19/07/05 
Page 5 of 14 
Use of a non-treponemal test was not recorded for 44 (6%) of cases. There was highly variable 
use of dark ground microscopy (DGM) between Regions, and DGM was positive for around 
40% of tests performed. The total of 107 DGM were performed by 32 (30%) clinics, with 17 
clinics performing one test, 4 clinics two tests, 1 clinic three tests, 2 clinics four tests, 2 clinics 
five tests, and seven, eight, nine, ten, thirteen and fourteen tests, one clinic each. Very little use 
was made either of the polymerase chain reaction (17 tests, 2 positive) or direct fluorescent 
antibody tests (8 tests, none positive).  
 
Six hundred and ninety six (89%) cases were tested for other sexually transmitted infections, 
and a total of 281 diagnostic codes were recorded for 220 cases, including the following: 
uncomplicated genital gonorrhoea (52), non-specific urethritis (43), uncomplicated genital 
chlamydial infection (40), first episode anogenital condylomata (18), first episode anogenital 
herpes simplex infection (12), viral hepatitis (6), complicated genital infection (2), trichomoniasis 
(5) antigen positive hepatitis B infection (1) and donovanosis (1). Table 1 shows the uptake of 
HIV testing; this measure included cases for whom testing was performed as well as 80 (10%, 
range 0-31%) cases already known to have HIV infection. There were 43 new diagnoses of HIV 
infection, most of which (32, 74%) affected homosexual or bisexual men, although uptake of 
HIV testing varied by as much as 25% between Regions. Nationally, testing was declined by 
130 (17%, range 0-24%) cases, not offered to 16 (2%, range 0-22%) cases, not documented for 
24 (3%, range 0-14%) cases and this question was not answered for 9 (1%, range 0-6%) cases. 
 
Treatment 
 
Nationally, parenteral treatment was the first treatment choice for 527 (67%, range 45-100%) 
cases, with approximately equal use of benzathine penicillin G (BPG) and procaine penicillin G 
(PPG) (including 11 Bicillin treatments) for 262 (50%, 0-97%) and 260 (49%, 3-100%) cases 
respectively (Table 2). An oral treatment was the first treatment choice for 223 (28%, range 0-
52%) cases (Table 3), with doxycycline as the only oral treatment comprising 192 (86%, range 
50-100%) of oral treatments (Table 4). Fourteen cases (2%, range 0-6%) were not treated. Ten 
(2%, range 0-11%) cases were treated by another clinic and treatment was not known, and no 
report of treatment was received for the remaining 7 (1%, range 0-6%) cases. 
  
The most common dose of PPG was with the 750mg dose (Table 2). Sixty seven (26%) PPG 
treatments were with doses  >750mg, comprising 2 grams (19 treatments), 0.9 grams (12 
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treatments), 0.8 grams (7 treatments), 1.2 grams (7 treatments), 2.4 grams (7 treatments), 2.67 
grams (one treatment), 1.8 grams (one treatment), Jenacillin A 3.6ml (2 treatments), one 
treatment each of Jenacillin A 4ml, 7.2 and 8 ml, one treatment with Jenacillin (not specified) 
4ml, Bicillin 1.2 grams (2 treatments), Bicillin 3 ml (one treatment), and Bicillin 0.8 grams (4 
treatments). Of these, only 28 (42%) were treatments for early latent syphilis, and only 27 (40%) 
were treatments for cases with HIV infection.  
 
In 14 (5%) instances treatment was with a dose <750mg PPG, comprising Jenacillin A 2.4ml (6 
treatments), PPG 0.6 grams (5 treatments), Jenacillin (not specified) 2.4mls (2 treatments), and 
250mg (one treatment). There were 5 (2%) treatments with long-acting PPG 2 grams. The dose 
used was not clear for 11 (4%) treatments. In one Region amoxycillin plus probenecid was used 
for 3 cases for weekend treatment to substitute for PPG.    
 
Ninety four (36%) PPG treatments were for >10 days: 10 (4%) cases were treated for 12 days, 
37 (14%) for 14 days, 1 (0.5%) for 15 days, 39 (15%) for 17 days, 2 (1%) for 19 days, 1 (0.5%) 
for 20 days, 4 (2%) for 21 days and not specified for 7 (3%). Of cases treated for longer than 10 
days, only 46 (29%) were treatments for early latent syphilis and only 36 (23%) were treatments 
for cases with HIV infection. Nationally, 105 (40%) PPG treatments (of cases in 33 clinics in 14 
Regions) were with greater than 750mg and/or for longer than 10 days; 49 (47%) of these 
treatments were for early latent syphilis, 37 (35%) for cases with HIV infection, and 76 (72%) for 
early latent syphilis and/or cases with HIV infection. 
 
Doxycycline was used to treat 195 (25%) cases, including three treatments combined with 
azithromycin. The recommended regimen of 100mg twice daily (bd) for 14 days was used in 
104 (53%) cases. However, 91 (47%) treatments were with a variety of other regimens, 
including treatment with larger doses and/or longer treatment intervals, once daily treatment and 
some combination treatments. Of these, 75 (82%) bd treatments were with >100mg bd and/or 
for longer than 14 days; 33 (44%) of these treatments were for early latent syphilis, 18 (24%) for 
cases with HIV infection, and 46 (61%) for early latent syphilis and/or cases with HIV infection. 
The remaining 16 (18%) treatments were with a variety of once daily regimens (Table 4). 
 
Of 123 cases who also had HIV infection, 88 (72%, range 0-100%) and 31 (25%, range 0-
100%) received parenteral and oral treatments respectively, as treatments of first choice; 2 (2%) 
cases were treated elsewhere and treatment was not known, treatment was not recorded for 
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one (1%) case and one (1%) case was not treated. Of the parenteral treatments used to treat 
cases with HIV infection, 56 (64%) were with PPG, 15 (17%) with 2 dose of BPG, 9 (10%) with 
1 dose of BPG, 6 (7%) with 3 doses of BPG, one (1%) with benzyl penicillin G, and one (1%) 
with ceftriaxone. Of the 56 treatments with PPG, 15 (27%) were for 10 days, 2 (4%) for 12 days, 
6 (11%) for 14 days, 1 (2%) for 15 days, 25 (45%) for 17 days, 1 (2 %) for 19 days, 1 (2 %) for 
21 days, and not stated for 5 (9%). A total of 27 (22%) cases with HIV infection were treated 
with doxycycline. 
 
There were 25 treatments involving the use of probenecid, 13 of 15 treatments with amoxycillin 
(87%), and 12 treatments with PPG (including one treatment with Bicillin). Of the latter, 5 
treatments were for early latent syphilis (all of these were with doses >750 mg for 17-21 days), 
5 treatments for secondary syphilis (also with doses >750 mg for 14-24 days), and the 
remaining two treatments were for primary syphilis, one with 2 grams of PPG for 17 days.  
 
There were 29 repeat treatments; in three cases re-infection was reported, and no cases of 
relapse or treatment failure were reported. Eleven initial treatments with PPG were repeated: 6 
with doxycycline treatments, two with erythromycin 500mg twice daily for 14 days, one with 
azithromycin one gram stat, one with two doses of BPG, and the remaining re-treatment was 
not specified. Nine initial treatments with BPG were repeated: 6 treatments with doxycycline and 
3 treatments with PPG. Six initial treatments with doxycycline were repeated: three with BPG, 
two with higher dose doxycycline regimen and one with azithromycin 500mg PO daily for 10 
days. Two initial treatments with a stat dose of azithromycin were each repeated with 
azithromycin 500mg once daily for 10 days. One ceftriaxone treatment was repeated with a 
course of erythromycin treatment. 
 
Nationally, 509 (65%, range 43-100%) treatments were directly observed, but these were nearly 
all parenteral treatments: 503 of 527 (95%) parenteral treatments were reported as directly 
observed. The remaining six cases comprised 5 oral treatments (1 for a case with HIV infection) 
and an unknown treatment. 
 
Advice about adverse drug reactions was received by 516 (66%, range 0-87%) cases. There 
were a total of 50 (6%, range 0-23%) cases affected by adverse events, comprising 35 (7%) 
and 15 (7%) cases receiving 527 parenteral and 223 oral treatments respectively. Fourteen of 
the oral treatment events were with doxycycline, and one with amoxycillin. The following 50 
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adverse reactions affecting 48 cases were reported:  Jarish-Herxheimer reaction (12), rash (11), 
paraesthesia/pain symptoms (6), fever (4), fainting (3), nausea (3), vomiting (3), diarrhoea (2), 
flu-like symptoms (1), lower limb oedema (1), panic attack (1), procaine reaction (1), pruritis (1), 
weight loss (1) and 3 non-specified events; there was no description of the adverse reactions 
affecting two cases. A course of corticosteroids was prescribed for 33 cases (4%, range 0-14%, 
in 10 Regions). The indications for use of corticosteroids were as follows: specific prevention of 
the Jarish-Herxheimer reaction (12), treatment of the Jarish-Herxheimer reaction (3), 
prophylactic use (3), treatment of a possible Jarish-Herxheimer reaction (1), treatment of 
choroidretinitis (1) and treatment of cranial nerve palsy (1). In 12 cases no information was 
presented to explain the use of corticosteroids. Three corticosteroid treatments were during 
pregnancy – one for possible Jarish-Herxheimer reaction, and not specified for the other two 
cases. 
 
 
  
Discussion 
 
This is the first UK national audit of early syphilis management, and the first national audit to 
provide clinical performance data aggregated by Regions and NHS Trusts. Over one quarter of 
cases in England and most cases in Scotland and Northern Ireland were sampled. Data has 
rapidly been disseminated to Chairs of Regional Audit Groups to facilitate comparative and 
interventional work that might lead to maintaining or improving practice.  
 
The absence of symptoms in some cases of primary and secondary syphilis, reporting of 
symptoms in some cases of early latent syphilis, as well as use of higher doses and longer 
durations of PPG regimens, suggests unsatisfactory use of diagnostic codes for case definition. 
However, it is possible that some treatments of primary syphilis pre-empted, or took place 
before, the appearance of symptoms (e.g. where epidemiological treatment took place).  
 
The PHLS Syphilis Serology Working Group5 recommended that use of the FTA abs test is 
reserved for discrepant results between EIA and TPPA/TPHA tests, although this 
recommendation is not directly referred to in the CEG Guidelines.2 The observation that 62% of 
FTA abs tests were carried out when both an EIA and either the TPPA or TPHA were positive 
suggests either frequent use of the FTA abs test for very early diagnosis, or overuse of the FTA 
abs test for confirmation. The much greater use of the TPPA test compared to the TPHA test 
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probably reflects the greater laboratory convenience of use of the former test. It is noteworthy 
that the commonly used tests do not have 100% sensitivity in primary syphilis, emphasising the 
importance of repeat testing. DGM was demonstrated to be a useful diagnostic tool in this audit 
with positivity rates of up to 100%. A survey conducted by the British Co-operative Clinical 
Group (BCCG) of BASSH in 2002 has, however, shown that 35% of clinics were not confident 
of their ability to detect treponemes on DGM.6  The very low use of the two other main direct 
detection methods, PCR and DFA, probably reflects lack of data about the relative contribution 
of these tests to earlier and/or increased detection of early syphilis. DGM is relatively easier to 
provide than PCR and DFA. This Audit supports the recommendation of a recent evaluation,7 
clearly showing the usefulness of DGM in the early diagnosis of primary and secondary syphilis 
and that DGM should be available in all genitourinary medicine clinics.  
 
There was an important number of cases who received treatment doses and or durations 
greater than those recommended by the CEG guidelines. This includes 38% of doxycycline bd 
treatments with >100mg bd and/or for longer than 14 days, and 40% of PPG treatments with 
greater than 750mg and/or for longer than 10 days. Treatments in excess of the recommended 
doxycycline regimen in early syphilis may reflect concern about reported treatment failure with 
the recommended regimen for doxycycline,8 treatment modifications because of drug 
interactions, concern about possible asymptomatic neurosyphilis, or the weak evidence base 
supporting the currently recommended doxycycline treatment for early syphilis.  The once daily 
treatments with doxycycline may reflect treatment simplification to encourage adherence. Most 
use of higher doses and longer durations of PPG regimens was found in cases with early latent 
syphilis or with HIV infection, although 28% of PPG treatments in excess of those 
recommended by the National Guidelines were for neither early latent syphilis nor HIV infection 
and might be explained by concern about possible asymptomatic neurosyphilis. By contrast, 
based on the recommendation in the National Guidelines that cases with HIV infection are 
treated “as for neurosyphilis,” there is considerable under-treatment of early syphilis in cases 
with HIV infection.2 
 
Conclusions and suggested areas for practice improvement/intervention 
 
Increased use of pre-treatment non-treponemal tests to 100% is needed in some Regions. More 
use should be made of DGM; training is available in the UK to support increased use of DGM 
(details available on the BASHH website). HIV infection is particularly important in early syphilis 
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and some Regions should consider interventions to improve uptake of HIV testing. More 
research is needed to determine the role of direct detection methods in early syphilis diagnosis.  
 
There was a considerable amount of treatment in excess of that recommended by the UK 
National Guidelines for early syphilis management, not all attributable to treatment of cases with 
HIV infection. This suggests inappropriate use of diagnostic codes or, particularly with regard to 
doxycycline treatments, lack of confidence among clinicians in the currently recommended 
treatments. Further work may be needed to improve the definition or appropriate use of the 
early syphilis diagnostic codes. Alternatively, increased stakeholder involvement in the writing of 
the UK guidelines for early syphilis management, such as that described in a recent article on 
guideline development,9 may improve use of recommended treatments. Based on the National 
Guidelines2 there is considerable under-treatment of early syphilis in cases with HIV infection 
that may improve with the publication of guidelines on treatment of acquired syphilis in HIV 
infection.10 
 
Detailed data, aggregated by Region, are available on the BASHH website: http://www.bashh.org/committees/nag/index.htm 
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Table 1.   Use of diagnostic tests in early syphilis (n=781 unless otherwise stated) 
Test  
Number of tests 
done (%) 
  Regional      
ranges (%) 
    Percentage 
positive tests 
(regional range)  
Treponemal enzyme immunoassay (EIA) 695 (89) 18-100 98 (89-100) 
Treponema pallidum particle agglutination assay (TPPA) 524 (67) 1-100 99 (89-100) 
Treponema pallidum haemagglutination assay (TPHA) 229 (28) 0-98 96 (78-100) 
Fluorescent treponemal antibody absorption test (FTA abs) 182 (23) 0-78 91 (40-100) 
Venereal Diseases Research Laboratory (VDRL) 531(68) 4-100 80 (0-100) 
Rapid plasma reagin test (RPR) 298 (38) 0-100 85 (50-100) 
VDRL or RPR 737 (94) 50-100 84 (44-96) 
Direct fluorescent antibody (DFA) 8 (1) 0-5 0 (0) 
Polymerase chain reaction (PCR) 18 (2) 0-6 11 (0-100) 
Dark ground microscopy (all cases) 107 (14) 0-40 37 (0 -100) 
Dark ground microscopy (primary syphilis, n=279) 80 (29) 0-82 41 (0-100) 
Screening for other STIs 696 (89) 76-97 See text 
HIV testing - uptake 602 (77) 69-94 6 (0-10)* 
Pregnancy testing (n = 116) 18 (16) 0-53 Not audited 
*Newly diagnosed HIV infection only, denominator is total cases minus previously diagnosed cases 
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Table 2.   Initial parenteral treatments for early syphilis (n=527) 
Parenteral treatment 
Number of 
treatments (%) 
Regional 
ranges % 
Procaine penicillin G 260 (49) 3-100 
Use of 750mg dose* 163 (63) 32-100 
Treatment for 10 days 159 (61) 36-100 
Benzathine penicillin G: 2 doses 188 (36) 0-93 
Benzathine penicillin G: 1 dose 62 (12) 0-39 
Benzathine penicillin G: 3 doses 12 (2) 0-20 
Ceftriaxone 3 (0.6) 0-4 
Benzyl penicillin 2 (0.4) 0-3 
 
*Includes 11 treatments with Bicillin  
†750mg, 750,000IU, Jenacillin A 3.3ml, Jenacillin A 3ml and Jenacillin (not specified) 3mls were  
counted in as 750 mg doses of procaine penicillin G   
 
 
 
 
 
Table 3.   Initial oral treatments for early syphilis (n=223) 
Oral treatment 
Number of 
treatments (%) 
Regional ranges 
% 
Doxycycline*  192 (86) 50-100 
Use of 100mg twice daily 14 days regimen 104 (54) 0-100 
Amoxycillin† 15 (7) 0-20 
Azithromycin  8 (4) 0-25 
Erythromycin  4 (2) 0-11 
Azithromycin plus doxycycline  3 (1) 0-50 
Oxytetracycline  1 (0.5) 0-7 
*3 doxycycline treatments combined with azithromycin excluded 
†2 treatments without probenecid  
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Table 4.   Initial treatments with doxycycline for early syphilis (n = 195)  
Doxycycline treatment Number of treatments (%) 
Doxycycline 100mg bd for 14 days 103 (53) 
Doxycycline 100mg bd for 14 days plus benzathine penicillin 2.4 grams x1 IM  1 (0.5) 
Doxycycline 200mg bd for 28 days 26 (13) 
Doxycycline 200mg bd for 14 days 16 (8) 
Doxycycline 100mg bd for 28 days 7 (4) 
Doxycycline 300mg od for 14 days 7 (4) 
Doxycycline 100mg bd for 21 days 6 (3) 
Doxycycline 100mg tds for 21 days 6 (3) 
Doxycycline 200mg bd for 21 days 3 (1.5) 
Doxycycline 200mg od for 14 days 3 (1.5) 
Doxycycline 300mg od for 21 days 3 (1.5) 
Doxycycline 100mg bd for 20 days 2 (1) 
Doxycycline 100mg tds for 28 days 2 (1) 
Doxycycline 100mg od for 21 days  1 (0.5) 
Doxycycline 100mg for 21 days (dosing not specified)  1 (0.5) 
Doxycycline 100mg tds for 14 days 1 (0.5) 
Doxycycline 100mg mane, 200mg nocte 14 days 1 (0.5) 
Doxycycline 100mg bd for 30 days 1 (0.5) 
Doxycycline 200mg mane, 100 mg nocte for 21 days 1 (0.5) 
Doxycycline 200mg tds for 21 days 1 (0.5) 
Doxycycline 100mg tds 14 days plus azithromycin 1g stat  1 (0.5) 
Doxycycline 100mg bd 28 days plus azithromycin 1g stat  1 (0.5) 
Doxycycline 300mg od for 21 days plus azithromycin 1g stat  1 (0.5) 
IM=intramuscular; bd=twice daily; od=once daily; tds=thrice daily; stat=single dose 
 
END. 
